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Background-—Low 25-hydroxyvitamin D levels are associated with an increased risk of cardiovascular events, but the effect of
vitamin D supplementation on markers of vascular function associated with major adverse cardiovascular events is unclear.
Methods and Results-—Weconducted a systematic review and individual participantmeta-analysis to examine the effect of vitamin D
supplementation on flow-mediated dilatation of the brachial artery, pulse wave velocity, augmentation index, central blood pressure,
microvascular function, and reactive hyperemia index.MEDLINE, CINAHL, EMBASE,CochraneCentral Register of Controlled Trials, and
http://www.ClinicalTrials.govwere searcheduntil the endof 2016without language restrictions. Placebo-controlled randomized trials
ofat least4 weeksdurationwere included. Individual participantdataweresought from investigatorson included trials. Trial-levelmeta-
analysiswas performed using random-effectsmodels; individual participantmeta-analyses used a 2-stage analytic strategy, examining
effects inprespecifiedsubgroups. 31 trials (2751participants)were included; 29 trials (2641participants) contributeddata to trial-level
meta-analysis, and24 trials (2051participants) contributed to individual-participant analyses.VitaminD3daily doseequivalents ranged
from900 to5000 IU; durationwas4 weeks to12 months. Trial-levelmeta-analysis showednosignificant effect of supplementation on
macrovascularmeasures(flow-mediateddilatation,0.37%[95%confidence interval,0.23to0.97];carotid-femoralpulsewavevelocity,
0.00 m/s [95% confidence interval, 0.36 to 0.37]); similar results were obtained from individual participant data. Microvascular
function showed a modest improvement in trial-level data only. No consistent benefit was observed in subgroup analyses or between
different vitamin D analogues.
Conclusions-—Vitamin D supplementation had no significant effect on most markers of vascular function in this analysis. ( J Am
Heart Assoc. 2018;7:e008273. DOI: 10.1161/JAHA.117.008273.)
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SYSTEMATIC REVIEW AND META-ANALYSIS
L ow circulating levels of 25-hydroxyvitamin D (25(OH)D)have been associated with a wide range of illness states
and physiological derangements. Within the field of car-
diometabolic medicine, low 25(OH)D levels have been asso-
ciated with higher levels of blood pressure (BP), with diabetes
mellitus, stroke, myocardial infarction, and heart failure1,2 in
observational studies. Vitamin D affects hundreds of gene
targets and has effects on a wide variety of cell types and
organ systems, including the heart and vascular system.3,4
Several pathophysiological pathways have been postulated to
explain the observed associations between low 25(OH)D
levels and cardiovascular disease, including effects on arterial
stiffness, endothelial function, cytokine secretion, vascular
endothelial growth factor, and cellular calcium influx.4
Despite a sound rationale for improved cardiovascular
health with vitamin D supplementation, results from inter-
vention trials have been less encouraging. A recent individual
participant data (IPD) meta-analysis reported that vitamin D
supplementation had no significant effect on BP,5 even in
those participants with low baseline 25(OH)D levels or with
high baseline BP. Similarly, only marginal effects were
observed on glycemic control in a meta-analysis of vitamin
D supplementation in participants with diabetes mellitus.6
Meta-analyses of cardiovascular outcomes show no effect of
vitamin D supplementation on myocardial infarction or stroke,
but suggest a possible effect in reducing new diagnoses of
heart failure.7 It is important to note that these meta-
analyses include mostly trials performed in participants at
risk for falls or with osteoporosis and may therefore not be
generalizable. Several large trials of vitamin D supplementa-
tion with adequate power to detect reductions in cardiovas-
cular events are due to report over the next few years, but
the first of these trials did not report any reduction in
cardiovascular event rates in a population of older people in
New Zealand.8
These results call into question the causal link between
vitamin D status and vascular health. Results from trials
investigating the effect of vitamin D supplementation on
aspects of vascular health other than BP have shown mixed
results. Arterial stiffness and endothelial function measures
are validated markers of cardiovascular disease risk and
major adverse cardiac events, but the beneficial impact of
vitamin D supplementation on these markers is unclear. We
therefore performed a systematic review with meta-analysis
of trial-level and individual participant-level data to ascertain
whether (1) vitamin D supplementation improves measures of
arterial stiffness and endothelial function and (2) certain
subgroups of individuals are more likely to benefit.
Methods
Data Sharing Statement
To preserve the rights of data owners, and as agreed with
those who contributed data sets for this analysis, the data,
analytical methods, and study materials will not be made
available to other researchers for the purposes of reproducing
the results or replicating the procedure.
Review Design and Search Strategy
We conducted a systematic review according to a prespecified
protocol, which was registered on the PROSPERO database of
systematic reviews. The protocol is accessible at: (http://
www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CR
D42012002816). Ethics committee approval was not
required because no new data were collected as part of
this review. We included randomized controlled trials, which
compared vitamin D or analogues with placebo, with a
minimum exposure period of 4 weeks. The following
databases were searched from inception to end of Decem-
ber 2016: Medline, EMBASE, CINAHL, ClinicalTrials.gov, and
the Cochrane central register of controlled trials. Gray
literature was sought using Google, and references of
included studies were hand-searched for further candidate
trials. Only trials where a full published trial report was
available were included; trials published in abstract form
only were excluded.
Trial Selection
Trials with changes in the following vascular markers were
included: brachial artery flow-mediated dilatation; reactive
hyperemia index measures using finger plethysmography;
Clinical Perspective
What Is New?
• This is the first individual participant data meta-analysis
examining the effect of vitamin D analogues on markers of
vascular function that are surrogates for cardiovascular
events.
• No consistent effect was found at trial level or on analysis of
individual participant-level data of supplementation on
measures of endothelial function, arterial stiffness, or
central blood pressure.
• No subgroup benefited consistently on analysis of individual
participant data.
What Are the Clinical Implications?
• This analysis did not find convincing evidence of benefit
from Vitamin D supplementation on a range of markers of
vascular function.
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pulse wave velocity (PWV) and pulse wave analysis; central
aortic BP derived from peripheral artery tonometry; microvas-
cular function measured using acetylcholine iontophoresis;
and laser Doppler perfusion imaging. Studies with any
baseline 25(OH)D level were eligible for inclusion. The
following interventions were eligible for inclusion: vitamin D2
(ergocalciferol), vitamin D3 (cholecalciferol), calcitriol (1,25
hydroxyvitamin D3), 1-alpha-vitamin D, paricalcitol, and
doxerocalciferol. Control groups receiving placebo were used
and those receiving placebo plus cointervention were
included, provided both arms of the study received the
cointervention. A minimum of 4 weeks of therapy was
necessary for inclusion to ensure sufficient time for vascular
markers to change. Studies from both primary and sec-
ondary care or population settings were included; no
restrictions were placed on sex or ethnicity. Studies
recruiting participants less than 16 years old were not
included, but in contrast to our previous review,5 we did
include studies of participants on renal replacement therapy
(hemodialysis or peritoneal dialysis) given their very high
cardiovascular risk and the current interest in using vitamin
D supplementation therapy in this group.
Data Extraction
Data were extracted independently by 2 researchers (L.A.B.
and M.D.W.) and differences resolved by consensus. Baseline
trial population data were identified, including age, sex,
ethnicity, diabetes mellitus, kidney function, history of
cardiovascular events, history of hypertension, baseline BP,
and baseline use of angiotensin-converting enzyme (ACE)
inhibitors, angiotensin receptor blockers, and statins. For
each measure of vascular function, we recorded change in the
outcome in each group between baseline and the last follow-
up visit. Study authors were contacted if data were incom-
plete or ambiguous in primary reports.
IPD Collection
Lead authors for each included trial were contacted and
invited to contribute individual-level participant data. Data
were anonymized and transferred using a standard template
before cleaning and incorporation in the final data set.
Individual-level participant data were sought for age, sex,
body mass index, baseline and follow-up 25(OH)D level,
baseline medication use including ACE inhibitors and
angiotensin receptor blockers, baseline estimated glomerular
filtration rate (eGFR), total cholesterol, serum calcium and
parathyroid hormone (PTH), presence of diabetes mellitus
and previous vascular events, baseline and follow up BP and
cholesterol, and baseline and follow-up measures of vascular
function.
Risk of Bias Assessment
Risk of bias was evaluated by 2 authors independently, with
discrepancies resolved by consensus. We assessed each
included study for risk for bias using the following fields from
a risk of bias checklist9: quality of random allocation
concealment, intention-to-treat analysis, blinding of outcome
assessors, treatment and control group comparability, clear
definition of inclusion and exclusion criteria, participant
blinding to allocation, and description of withdrawals and
dropouts. Funnel plots were generated and inspected for
evidence of publication bias, supplemented by Egger’s test for
funnel plot asymmetry.
Statistical Analysis
Meta-analysis at the trial level was performed using RevMan
5.3 software (Cochrane Collaboration). For all analyses,
random-effects and fixed-effects meta-analyses using a
weighted least-squares approach were performed. For out-
comes measured with the same technique and same units
(most brachial-artery flow-mediated dilatation [FMD] mea-
sures, reactive hyperemia index, augmentation index [AIx],
central BP, and subgroups of PWV), results were expressed as
mean difference between groups. For comparisons where
dissimilar units were combined, results were expressed as
standardized mean difference (SMD). Heterogeneity was
assessed using the I2 statistic. Trial-level meta-regression
Figure. PRISMA diagram showing trial selection.
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was undertaken for FMD, PWV, and augmentation index
outcomes, regressing treatment effect on daily dose equiva-
lent (for trials using vitamin D3) and trial duration in months.
Metaregression was not used for other outcomes because
there were too few to produce reliable results. Metaregression
was undertaken using Comprehensive Meta Analysis tools
software (version 3; Biostat, Englewood, NJ).
A 2-stage analysis was used for IPD.10 For each trial, or
subgroup within each trial, mean outcome values at follow-up
in each group were calculated and adjusted for baseline
outcome values using ANCOVA (SPSS version 24; IBM,
Armonk, NY). These values were then combined using RevMan
software as described above. For those trials using more than
1 type or dose of vitamin D, the vitamin D arms were analyzed
as a single arm. The following prespecified subgroup analyses
were performed: diabetes mellitus versus no diabetes melli-
tus; baseline systolic BP of no greater than 140 mm Hg
versus greater than 140 mm Hg; diastolic BP of no greater
Table 1. Measurements From Included Studies
Title and Year
Preparation
Tested FMD PWV AIx RHI Central BP
Microvascular
Function
Included in
IPD Analysis?
Alborzi 200811 Paricalcitol X No
Sugden 200812 Vitamin D2 X Yes
Witham 201013 Vitamin D3 X Yes
Harris 201114 Vitamin D3 X Yes
Gepner 201215 Vitamin D3 X X X X Yes
Larsen 201216 Vitamin D3 X X X Yes
Marckmann 201217 Vitamin D3 X X X Yes
Sokol 201218 Vitamin D2 X Yes
Stricker 201219 Vitamin D3 X X X Yes
Witham 201220 Vitamin D2 X Yes
Breslavsky 201321 Vitamin D3 X Yes
Hewitt 201322 Vitamin D3 X No
Witham 201323 Vitamin D3 X X Yes
Witham 201324 Vitamin D3 X Yes
Witham 201325 Vitamin D3 X X X X X Yes
Yiu 201326 Vitamin D3 X X No
Dreyer 201427 Vitamin D2 X X Yes
Martins 201428 Vitamin D3 X No
Mose 201429 Vitamin D3 X X X Yes
Ryu 201430 Vitamin D3 X X No
Zoccali 201431 Paricalcitol X Yes
Garg 201532 Vitamin D3 X X Yes
Pilz 201533 Vitamin D3 X Yes
Thethi 201534 Paricalcitol X No
Witham 201535 Vitamin D3 X X X Yes
Barchetta 201636 Vitamin D3 X Yes
Borgi 201737 Vitamin D2 X No
Bressendorff 201638 Vitamin D3 X X X Yes
Dalan 201639 Vitamin D3 X X Yes
Forouhi 201640 Vitamin D2
Vitamin D3
X Yes
Hin 201741 Vitamin D3 X X Yes
AIx indicates augmentation index; BP, blood pressure; FMD, flow-mediated dilatation of the brachial artery; IPD, individual participant data; PWV, pulse wave velocity; RHI, reactive
hyperemia index.
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than 90 mm Hg versus greater than 90 mm Hg; baseline PTH
level of above versus below median level for the IPD set;
baseline adjusted serum calcium level and baseline total
cholesterol above versus below median level for the individual
participant data set; estimated glomerular filtration rate
(eGFR) 60 mL/min per 1.73 m2 or above versus subgroups
of eGFR below 60 mL/min per 1.73 m2; baseline 25(OH)D
level of less than 25, 25 to 50, and greater than 50 nmol/L;
and baseline ACE inhibitor versus no ACE inhibitor use. For
analyses of ACE inhibitor use, participants taking angiotensin
receptor blockers were excluded given their similar, but not
identical, biological effects. Subgroups for analysis were
selected on the basis of possible mechanisms by which
vitamin D might act (eg, through effects on the renin-
angiotensin system or by suppressing PTH),4 to explore
groups thought to be most likely to benefit (eg, high BP, low
25(OH)D levels), and to identify disease populations that
might be targeted by future studies (diabetes mellitus, chronic
kidney disease [CKD]). For CKD, subgroups of eGFR 45 to 59,
30 to 44, 15 to 29, and <15 mL/min per 1.73 m2 were used
where sufficient numbers of participants were available for
the outcome; for outcomes with small numbers of partici-
pants, these subgroups were collapsed into a category eGFR
<60 mL/min per 1.73 m2. Participants on dialysis were
included in the <15 mL/min per 1.73 m2 subgroup.
Results
A total of 31 trials, involving 2751 participants, were eligible
for inclusion in the review.11–41 Of these, 29 trials (2641
participants) had data suitable for inclusion in the trial-level
meta-analyses; IPD were obtained from 24 trials (2051
participants). The PRISMA flowchart is shown in Figure. One
study that did not include data in the published article suitable
for trial-level meta-analysis36 provided IPD data and was
included in the IPD analyses. Study size ranged from 24 to
305 participants; vitamin D3 was the most common inter-
vention, being used in 23 of 31 (74%) of trials. The daily dose
equivalent given in trials of vitamin D3 ranged from 900 to
5000 IU, and the duration of administration ranged from
4 weeks to 12 months. Paricalcitol was the only activated
vitamin D analogue used in studies included in this review.
Table 1 shows which vascular outcomes were measured in
each included trial, and baseline trial characteristics are
shown in Table 2.
Risk of Bias Assessment
Overall risk of bias was low. Most trials (27 of 31) reported
clear evidence of effective allocation concealment, and most
trials reported clear evidence for masking of participants (30
of 31), healthcare professionals (30 of 31), and outcomesTa
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assessors (29 of 31). Groups were comparable at baseline in
27 of 31 trials, dropouts were clearly described in 27 of 31
trials, but analysis was clearly by intention to treat in only 16
of 31 trials. A full description of the quality assessment for
each trial is shown in Table 3. Funnel plots showed no
asymmetry for any of the vascular outcomes; Egger’s test was
calculated only for those outcomes with at least 10 trials to
ensure reliability; this was nonsignificant for FMD (P=0.18),
AIx (P=0.32), and PVW (P=0.70).
Trial-Level Data
Meta-analysis of trial-level data showed no significant
treatment effect of vitamin D analogues on FMD (mean
difference, 0.5%; 95% confidence interval [CI], 0.1 to 1.1;
P=0.12), PVW (SMD, 0.02; 95% CI, 0.13 to 0.17; P=0.81),
AIx (mean difference, 0.0%; 95% CI, 1.3 to 1.3; P=0.98),
reactive hyperemia index (mean difference, 0.02 units; 95%
CI, 0.11 to 0.14; P=0.79), or central BP. Microvascular
Table 3. Risk of Bias Assessment of Included Studies
Title and Year
Quality of
Allocation
Concealment
Analysis on
Intention to
Treat
No. and
Description
of Dropouts
Blinding—
Participants
Blinding—
Health Care
Providers
Blinding—
Outcome
Assessors
Comparable
Treatment and
Placebo Groups
Alborzi 200811 + + + + + + 
Sugden 200812 +  + + + + +
Witham 201013 + U + + + + +
Harris 201114 + U + + + + +
Gepner 201215 + + + + + + +
Larsen 201216 +  + + + + +
Marckmann 201217 +  + + + + +
Sokol 201218 + + U + + + +
Stricker 201219 + + + + + + 
Witham 201220 + U + + + + +
Breslavsky 201321 +  + U U U +
Hewitt 201322 + U + + + + +
Witham 201323 +  + + + + +
Witham 201324 + + + + + + +
Witham 201325 + + + + + + +
Yiu 201326 + + + + + + +
Dreyer 201427 + + + + + + +
Martins 201428 U + + + + + +
Mose 201429 + U + + + + +
Ryu 201430 U  + + + + +
Zoccali 201431 + + + + + + +
Garg 201532 U  + + + + +
Pilz 201533 + + + + + + +
Thethi 201534 U U U + + U +
Witham 201535 + + + + + + +
Barchetta 201636 +  + + + + +
Borgi 201737 + +  + + + +
Bressendorff 201638 + U + + + + +
Dalan 201639 + + U + + + 
Forouhi 201640 + + + + + + +
Hin 201741 + + + + + + +
 indicates high risk of bias; +, low risk of bias; U, unclear risk of bias.
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function measured by laser Doppler iontophoresis (SMD,
0.43; 95% CI, 0.09–0.76; P=0.01) showed a modest
improvement with vitamin D supplementation. Results are
shown in Table 4. Fixed-effects analyses showed similar
point estimates, but narrower CIs, leading to a significant
treatment effect for all vitamin D analogues on FMD (mean
Table 4. Trial-Level Analysis of Effect Size: Vitamin D Supplementation and Markers of Vascular Function
Outcome Intervention
No. of
Studies n
Random-Effects Fixed-Effects
I2Treatment Effect (95% CI) P Value Treatment Effect (95% CI) P Value
FMD (%) All 12 785 0.49 (0.13 to 1.11) 0.12 0.48 (0.06–0.90) 0.02 46%
D3 7 495 0.17 (0.49 to 0.84) 0.61 0.19 (0.30 to 0.67) 0.45 38%
D2 3 163 0.79 (1.04 to 2.62) 0.40 0.91 (0.39 to 2.21) 0.17 45%
Paricalcitol 2 103 1.72 (0.63–2.82) 0.002 1.72 (0.63–2.82) 0.002 0%
AIx (%) All 14 1030 0.0 (1.3 to 1.3) 0.98 0.0 (1.1 to 1.1) 0.98 25%
D3 14 1030 0.0 (1.3 to 1.3) 0.98 0.0 (1.1 to 1.1) 0.98 25%
D2 0      
Paricalcitol 0      
RHI, units All 3 217 0.02 (0.11 to 0.14) 0.79 0.02 (0.11 to 0.14) 0.79 0%
D3 2 130 0.02 (0.18 to 0.21) 0.86 0.04 (0.10 to 0.18) 0.61 37%
D2 1 87 0.05 (0.30 to 0.20) 0.70 0.05 (0.30 to 0.20) 0.70 
Paricalcitol 0    
PWV (all; SMD) All 16 1333 0.04 (0.11 to 0.20) 0.60 0.04 (0.07 to 0.15) 0.50 44%
D3 15 1304 0.05 (0.11 to 0.21) 0.52 0.04 (0.07 to 0.15) 0.45 47%
D2 2* 138 0.24 (0.57 to 0.10) 0.17 0.24 (0.57 to 0.10) 0.17 0%
Paricalcitol 0      
PWV (carotid-femoral
only; m/s)*
All 10 674 0.04 (0.32 to 0.41) 0.81 0.01 (0.20 to 0.21) 0.94 58%
D3 10 674 0.00 (0.32 to 0.41) 0.81 0.01 (0.20 to 0.21) 0.94 58%
D2 1 107 0.53 (1.34 to 0.28) 0.20 0.53 (1.34 to 0.28) 0.20 
Paricalcitol 0      
PWV (others; SMD) All 6 659 0.11 (0.06 to 0.28) 0.22 0.11 (0.04 to 0.27) 0.15 8%
D3 5 630 0.12 (0.06 to 0.30) 0.19 0.13 (0.03 to 0.29) 0.11 14%
D2 1 29 0.20 (0.93 to 0.53) 0.59 0.20 (0.93 to 0.53) 0.59 
Paricalcitol 0      
Microvascular
function (SMD)
All 3 140 0.43 (0.09–0.76) 0.01 0.43 (0.09–0.76) 0.01 0%
D3 2 111 0.37 (0.01 to 0.75) 0.05 0.37 (0.01 to 0.75) 0.05 0%
D2 1 29 0.65 (0.10 to 1.41) 0.09 0.65 (0.10 to 1.41) 0.09 
Paricalcitol 0      
Central SBP, mm Hg All 5 324 1.5 (5.6 to 2.6) 0.46 1.2 (3.8 to 1.4) 0.36 47%
D3 5 324 1.5 (5.6 to 2.6) 0.46 1.2 (3.8 to 1.4) 0.36 47%
D2 0      
Paricalcitol 0      
Central DBP, mm Hg All 5 324 0.8 (2.2 to 0.6) 0.28 0.8 (2.2 to 0.6) 0.28 0%
D3 5 324 0.8 (2.2 to 0.6) 0.28 0.8 (2.2 to 0.6) 0.28 0%
D2 0      
Paricalcitol 0      
AIx indicates augmentation index; CI, confidence interval; D2, vitamin D2 (ergocalciferol); D3, vitamin D3 (cholecalciferol); DBP, diastolic blood pressure; FMD, flow-mediated dilatation of
the brachial artery; PWV, pulse wave velocity; RHI, reactive hyperemia index; SBP, systolic blood pressure; SMD, standardized mean difference.
*Data from Forouhi et al40 contain comparisons of D3 vs placebo and D2 vs placebo. Only D3 analysis was included in “All” category for PWV analyses.
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difference, 0.5%; 95% CI, 0.1–0.9; P=0.02). On subgroup
analysis by treatment type, only paricalcitol showed a
significant treatment benefit on FMD (mean difference,
1.7%; 95% CI, 0.6–2.8; P=0.002); analysis for interaction
showed no significant difference between the paricalcitol
treatment effect and that for vitamin D3 (P=0.62) or vitamin
D2 (P=0.17). No significant difference was evident in the
effects of daily dosing versus intermittent dosing either for
FMD (mean difference, 0.85% [95% CI, 0.01–1.69] for daily
dosing versus 0.26% [95% CI, 0.58 to 1.11] for intermittent
dosing; P=0.06) or for PWV (SMD, 0.10 [95% CI, 0.04 to
0.23] for daily dosing versus 0.04 [95% CI, 0.34 to 0.26]
for intermittent dosing; P=0.40). Metaregression results for
daily dose equivalent and for trial duration are shown in
Table 5. No association between these factors and treat-
ment effect for PWV or AIx was found, but higher dose and
shorter trial length were associated with a slightly greater
treatment effect for FMD.
Individual Participant Data
Similarly, meta-analysis of IPD showed no significant treat-
ment effect on any of the vascular outcomes studied; no
effect was evident when PWV analyses were confined to
studies using carotid-femoral PWV. The main results for IPD
analysis are shown in Table 6. For most analyses, hetero-
geneity as shown by the I2 statistic was low to moderate.
Prespecified subgroup analysis of IPD data for each vascular
outcome (Tables 7 through 13) did not show any subgroup
consistently deriving significant benefit from vitamin D or
analogues; treatment/subgroup interaction analyses sug-
gested that participants with eGFR <60 mL/min per
1.73 m2 may be less likely to show improvements in FMD
or aortic diastolic BP with treatment, and those with 25(OH)D
levels <25 nmol/L may be more likely to show improvements
in reactive hyperemia index and AIx with treatment. Partic-
ipants with diabetes mellitus appeared to have a significantly
Table 5. Results of Trial-Level Metaregression
Outcome Moderator Variable
No. of
Trials
Random-Effects Fixed-Effects
Regression Coefficient UnitsRegression Coefficient (95% CI) P Value Regression Coefficient (95% CI) P Value
FMD (%) Trial duration 11 0.06 (0.11 to 0.01) 0.03 0.06 (0.10 to 0.01) 0.009 % per mo
Daily dose equivalent 6 0.14 (0.01–0.27) 0.03 0.14 (0.01–0.27) 0.03 % per 1000 units D3
PWV (SMD) Trial duration 16 0.01 (0.04 to 0.06) 0.77 0.02 (0.01 to 0.05) 0.18 SD per mo
Daily dose equivalent 15 0.07 (0.08 to 0.23) 0.35 0.06 (0.05 to 0.17) 0.29 SD per 1000 units D3
AIx (%) Trial duration 14 0.01 (0.05 to 0.04) 0.73 0.00 (0.04 to 0.03) 0.84 % per mo
Daily dose equivalent 14 0.10 (0.06 to 0.25) 0.22 0.09 (0.04 to 0.23) 0.18 % per 1000 units D3
AIx indicates augmentation index; CI, confidence interval; FMD, flow-mediated dilatation of the brachial artery; PWV, pulse wave velocity; SMD, standardized mean difference.
Table 6. IPD Analysis of Effect Size: Vitamin D Supplementation and Markers of Vascular Function
Outcome
No. of
Studies n
Mean Baseline
Value Across All
Groups (SD)
Random Effects Fixed Effects
I2Treatment Effect (95% CI) P Value Treatment Effect (95% CI) P Value
FMD (%) 10 655 5.6 (3.6) 0.03 (0.78 to 0.71) 0.93 0.17 (0.58 to 0.25) 0.44 63%
AIx (%) 11 832 27 (16) 0.1 (1.4 to 1.6) 0.91 0.0 (1.0 to 1.1) 0.96 39%
RHI, units 3 220 1.65 (0.81) 0.02 (0.12 to 0.08) 0.68 0.02 (0.12 to 0.08) 0.68 0%
PWV (all; SMD) 13 1154 ND 0.01 (0.16 to 0.13) 0.85 0.04 (0.15 to 0.08) 0.56 25%
PWV (carotid-femoral
only; m/s)
9 652 7.9 (2.8) 0.01 (0.31 to 0.30) 0.96 0.04 (0.25 to 0.17) 0.70 44%
PWV (others; SMD) 4 502 ND 0.02 (0.20 to 0.16) 0.83 0.05 (0.36 to 0.26) 0.75 0%
Microvascular function (SMD) 3 129 ND 0.36 (0.01–0.71) 0.05 0.36 (0.01–0.71) 0.13 0%
Central SBP, mm Hg 7 400 120.7 (23.9) 0.6 (3.2 to 1.9) 0.63 0.4 (2.4 to 1.6) 0.67 31%
Central DBP, mm Hg 7 400 76.5 (9.9) 0.4 (1.5 to 0.7) 0.48 0.4 (1.5 to 0.7) 0.48 0%
AIx indicates augmentation index; CI, confidence interval; DBP, diastolic blood pressure; FMD, flow-mediated dilatation of the brachial artery; IPD, individual participant data; ND, not done
because of heterogeneity of measurement methods; PWV, pulse wave velocity; RHI, reactive hyperemia index; SBP, systolic blood pressure; SMD, standardized mean difference.
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greater rise in aortic BP than those without diabetes mellitus.
For outcomes in both trial-level and IPD analysis that were
performed using SMD, standardizing SDs are given in
Table 14 to facilitate interpretation at the individual trial level.
Discussion
The present meta-analysis found little evidence to support the
hypothesis that supplementation of vitamin D or use of
vitamin D analogues can improve markers of cardiovascular
health. Our results were broadly consistent across a range of
vascular markers and interventions, and subgroup analyses
using IPD did not identify a subgroup that was more likely to
benefit from treatment—this remained true even for those
participants with the lowest 25(OH)D levels, with high
baseline BP, and with higher baseline PTH levels. Random-
effects and fixed-effects analyses gave very similar results in
the majority of analyses. Our results are consistent with our
Table 7. IPD Subgroup Analyses for FMD
Subgroup
No. of
Studies n
Mean Baseline
Value (%) (SD)
Random Effects Fixed Effects
I2
Treatment Effect (%)
(95% CI) P Value
P for
Interaction
Treatment Effect
(%) (95% CI) P Value
P for
Interaction
SBP >140 mm Hg 9 242 5.2 (3.2) 0.0 (1.1 to 1.0) 0.94 0.88 0.1 (0.6 to 0.5) 0.82 1.0 56%
SBP ≤140 mm Hg 9 376 5.9 (3.8) 0.1 (0.9 to 1.0) 0.90 0.1 (0.6 to 0.5) 0.79 58%
Baseline 25(OH)D
<25 nmol/L
6 89 5.7 (4.0) 0.3 (1.8 to 1.2) 0.65  0.1 (1.0 to 0.9) 0.92  43%
Baseline 25(OH)D
25 to 50 nmol/L
9 292 5.3 (3.3) 0.1 (1.2 to 1.0) 0.87 0.83 0.1 (0.7 to 0.5) 0.66 1.0 66%
Baseline 25(OH)D
>50 nmol/L
8 222 5.4 (3.4) 0.2 (1.1 to 0.7) 0.66 0.91 0.2 (0.9 to 0.4) 0.47 0.87 41%
DM 6 198 5.2 (3.5) 0.1 (1.1 to 1.4) 0.82 0.47 0.4 (0.5 to 1.2) 0.40 0.27 37%
No DM 7 454 5.7 (3.5) 0.4 (0.9 to 0.1) 0.14 0.3 (1.2 to 0.6) 0.55 63%
No ACEi or ARB 9 254 6.5 (3.6) 0.1 (2.0 to 2.2) 0.92  0.6 (1.3 to 0.1) 0.09  88%
ACEi, no ARB 7 171 5.4 (3.5) 0.4 (1.7 to 1.0) 0.58 0.69 0.2 (1.0 to 0.6) 0.64 0.46 47%
ACEi or ARB 7 297 5.0 (3.4) 0.7 (1.9 to 0.5) 0.28 0.52 0.7 (1.4 to 0.1) 0.03 0.84 60%
PTH >5.0 pmol/L 8 254 5.4 (3.6) 0.3 (1.5 to 0.9) 0.61 0.39 0.8 (1.5 to 0.2) 0.02 0.02 62%
PTH ≤5.0 pmol/L 7 230 5.7 (3.1) 0.3 (0.3 to 1.0) 0.30 0.3 (0.3 to 1.0) 0.30 0%
Ca >2.30 mmol/L 7 226 6.0 (3.4) 0.3 (0.3 to 1.0) 0.30 0.19 0.3 (0.3 to 1.0) 0.30 0.08 0%
Ca ≤2.30 mmol/L 7 371 5.2 (3.4) 0.5 (1.5 to 0.5) 0.30 0.5 (1.1 to 0.1) 0.09 56%
eGFR ≥60 mL/min
per 1.73 m2
6 382 5.6 (3.4) 0.5 (0.2 to 1.2) 0.18  0.6 (0.0–1.2) 0.04  27%
eGFR 45 to
59 mL/min
per 1.73 m2
5 59 5.3 (3.1) 0.1 (2.2 to 2.1) 0.94 0.60 0.3 (1.0 to 1.5) 0.66 0.67 55%
eGFR 30 to
44 mL/min
per 1.73 m2
3 38 4.5 (2.9) 1.0 (2.7 to 0.7) 0.27 0.11 1.0 (2.7 to 0.7) 0.27 0.08 0%
eGFR 15 to
29 mL/min
per 1.73 m2
1 24 3.4 (3.0) 3.1 (5.7 to 0.5) 0.02 0.009 3.1 (5.7 to 0.5) 0.02 0.007 
eGFR <15 mL/min
per 1.73 m2*
0         
Total cholesterol
≥4.60 mmol/L
8 223 5.4 (3.4) 0.9 (1.9 to 0.1) 0.07 0.23 1.0 (1.6 to 0.4) 0.002 0.06 51%
Total cholesterol
<4.60 mmol/L
8 283 5.6 (3.7) 0.1 (1.1 to 1.4) 0.83 0.2 (0.8 to 0.4) 0.60 69%
25(OH)D indicates 25-hydroxyvitamin D; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval; DM, diabetes mellitus;
eGFR, estimated glomerular filtration rate; FMD, flow-mediated dilatation of the brachial artery; IPD, individual participant data; PTH, parathyroid hormone; SBP, systolic blood pressure.
*Or on dialysis.
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previous work that failed to find a beneficial effect of vitamin
D therapy on BP5 and are also in accord with 2 recent, smaller
meta-analyses examining arterial stiffness and endothelial
function.42,43 One further recent meta-analysis, examining
only FMD, showed a slightly greater benefit (treatment effect
of vitamin D was 1.27% for FMD),44 perhaps attributable to
differences in both study selection and the data used; our
analysis had the benefit of access to IPD, which allowed us to
verify the accuracy of published data and data used in
previous meta-analyses. The results are also consistent with
recent data suggesting no effect of vitamin D supplementa-
tion on plasma N-terminal pro-B-type natriuretic peptide levels
or echocardiographic indices in older people after 12 months
of therapy.45
Table 8. IPD Subgroup Analyses for PWV
Subgroup
No. of
Studies N
Mean Baseline
Value (m/s)
(SD)*
Random Effects Fixed Effects
I2
Treatment Effect
(95% CI) (SMD) P Value
P for
Interaction
Treatment Effect
(95% CI) (SMD) P Value
P for
Interaction
SBP >140 mm Hg 9 396 8.9 (3.2) 0.1 (0.3 to 0.1) 0.21 0.49 0.1 (0.3 to 0.1) 0.21 0.43 0%
SBP ≤140 mm Hg 11 728 7.5 (2.6) 0.0 (0.2 to 0.2) 1.00 0.0 (0.2 to 0.1) 0.62 40%
Baseline 25(OH)D
<25 nmol/L
11 157 7.6 (2.8) 0.2 (0.2 to 0.5) 0.36  0.2 (0.2 to 0.5) 0.36  0%
Baseline 25(OH)D
25 to 50 nmol/L
12 508 8.0 (3.2) 0.1 (0.3 to 0.2) 0.67 0.17 0.1 (0.3 to 0.1) 0.38 0.15 39%
Baseline 25(OH)D
>50 nmol/L
10 482 7.8 (2.6) 0.0 (0.2 to 0.2) 0.81 0.33 0.0 (0.2 to 0.2) 0.76 0.33 12%
DM 6 130 8.5 (4.5) 0.1 (0.3 to 0.4) 0.65 0.30 0.1 (0.3 to 0.4) 0.65 0.30 0%
No DM 13 1021 7.8 (2.5) 0.1 (0.2 to 0.1) 0.32 0.1 (0.2 to 0.1) 0.32 0%
No ACEi or ARB 9 399 7.7 (3.1) 0.1 (0.3 to 0.2) 0.70  0.1 (0.3 to 0.1) 0.44  21%
ACEi, no ARB 7 203 8.5 (3.3) 0.2 (0.5 to 0.1) 0.17 0.62 0.2 (0.5 to 0.1) 0.17 0.62 0%
ACEi or ARB 8 364 8.1 (3.2) 0.0 (0.3 to 0.2) 0.68 0.58 0.0 (0.3 to 0.2) 0.68 0.58 0%
PTH >5.0 pmol/L 12 482 7.9 (2.9) 0.1 (0.3 to 0.1) 0.16 0.49 0.1 (0.3 to 0.1) 0.16 0.49 0%
PTH ≤5.0 pmol/L 12 594 7.9 (3.2) 0.0 (0.2 to 0.2) 0.97 0.0 (0.2 to 0.2) 0.95 12%
Ca >2.30 mmol/L 9 456 7.8 (3.5) 0.0 (0.2 to 0.2) 0.91 0.12 0.0 (0.2 to 0.2) 0.91 0.12 0%
Ca ≤2.30 mmol/L 10 496 8.0 (2.6) 0.2 (0.3 to 0.0) 0.11 0.2 (0.3 to 0.0) 0.10 2%
eGFR ≥60 mL/min
per 1.73 m2
10 897 7.8 (2.3) 0.0 (0.2 to 0.1) 0.57  0.0 (0.2 to 0.1) 0.55  5%
eGFR 45 to
59 mL/min
per 1.73 m2
6 76 7.2 (4.8) 0.3 (0.3 to 0.9) 0.35 0.34 0.2 (0.3 to 0.7) 0.41 0.45 12%
eGFR 30 to
44 mL/min
per 1.73 m2
3 27 8.8 (2.0) 0.8 (1.6 to 0.1) 0.07 0.07 0.8 (1.6 to 0.1) 0.07 0.07 0%
eGFR 15 to
29 mL/min
per 1.73 m2
2 8 13.7 (1.1) 0.1 (2.0 to 2.2) 0.95 0.93 0.1 (2.0 to 2.2) 0.95 0.93 0%
eGFR <15 mL/min
per 1.73 m2†
2 54 9.0 (4.9) 0.4 (0.1 to 1.0) 0.12 0.17 0.4 (0.1 to 1.0) 0.12 0.17 0%
Total cholesterol
≥4.60 mmol/L
11 651 7.8 (2.3) 0.1 (0.3 to 0.1) 0.24 0.54 0.1 (0.3 to 0.1) 0.24 0.49 0%
Total cholesterol
<4.60 mmol/L
11 398 7.7 (3.0) 0.0 (0.2 to 0.3) 0.83 0.0 (0.2 to 0.2) 0.87 23%
25(OH)D indicates 25-hydroxyvitamin D; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval; DM, diabetes mellitus;
eGFR, estimated glomerular filtration rate; IPD, individual participant data; PTH, parathyroid hormone; PWV, pulse wave velocity; SBP, systolic blood pressure; SMD, standardized mean
difference.
*Data only from studies measuring baseline carotid-femoral PWV.
†
Or on dialysis.
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Despite the large number of participants included in this
analysis, it is not possible to completely refute the possibility
that vitamin D or its analogues could still have a modest
benefit on vascular health. The markers measured in studies
included in this meta-analysis are subject to changes
attributed to differences in environment, diet, smoking,
medications, and operator skill; such factors require careful
use of protocols to standardize measurement and reduce
variability.46,47 The upper limit of the 95% CIs in our analyses
encompasses a 1% improvement in FMD, a 1% improvement
in AIx, a 0.3-m/s improvement in PWV, and a 5.6 mm Hg
improvement in aortic systolic BP. A 5 mm Hg reduction in
aortic systolic BP would be consistent with significant clinical
benefit, and a 1% improvement in FMD would be consistent
with an 8% to 13% reduction in cardiovascular event
rates.48,49 A trial published too recently to be included in
Table 9. IPD Subgroup Analyses for AIx
Subgroup
No. of
Studies n
Mean Baseline
Value (%) (SD)
Random Effects Fixed Effects
I2
Treatment Effect (%)
(95% CI) P Value
P for
Interaction
Treatment Effect (%)
(95% CI) P Value
P for
Interaction
SBP >140 mm Hg 9 214 33.3 (16.6) 0.8 (1.1 to 2.7) 0.39 0.31 0.8 (1.1 to 2.7) 0.39 0.26 0%
SBP ≤140 mm Hg 11 615 24.9 (14.6) 0.6 (2.5 to 1.4) 0.57 0.5 (1.7 to 0.7) 0.44 52%
Baseline 25(OH)D
<25 nmol/L
8 93 24.9 (14.9) 4.3 (11.0 to 2.4) 0.20  4.8 (7.8 to 1.7) 0.002  76%
Baseline 25(OH)D
25 to 50 nmol/L
10 357 25.8 (16.7) 0.1 (1.9 to 2.1) 0.92 0.22 0.0 (1.5 to 1.5) 0.99 0.006 30%
Baseline 25(OH)D
>50 nmol/L
8 342 28.6 (15.2) 0.5 (1.1 to 2.0) 0.58 0.17 0.5 (1.1 to 2.0) 0.58 0.002 0%
DM 7 163 26.1 (15.6) 2.0 (2.6 to 6.6) 0.40 0.37 0.4 (2.2 to 3.1) 0.75 0.68 61%
No DM 9 666 27.3 (15.7) 0.2 (1.4 to 1.1) 0.80 0.2 (1.3 to 0.9) 0.73 11%
No ACEi or ARB 9 209 23.1 (14.3) 0.2 (2.0 to 1.7) 0.86  0.2 (2.0 to 1.6) 0.85  4%
ACEi, no ARB 7 137 25.4 (12.6) 0.3 (1.6 to 2.2) 0.79 0.71 0.3 (1.6 to 2.2) 0.79 0.71 0%
ACEi or ARB 7 243 26.4 (12.7) 0.1 (2.1 to 1.9) 0.94 0.94 0.4 (1.9 to 1.2) 0.63 0.87 27%
PTH >5.0 pmol/L 9 282 25.3 (15.9) 0.1 (2.4 to 2.5) 0.96 0.89 0.3 (2.1 to 1.5) 0.73 0.62 43%
PTH ≤5.0 pmol/L 9 441 27.9 (16.9) 0.3 (1.3 to 1.8) 0.72 0.3 (1.3 to 1.8) 0.72 0%
Ca >2.30 mmol/L 5 286 28.3 (18.7) 0.0 (3.6 to 3.6) 1.00 0.45 0.1 (3.4 to 3.2) 0.96 0.39 11%
Ca ≤2.30 mmol/L 6 265 26.2 (13.3) 1.6 (0.4 to 3.6) 0.12 1.6 (0.4 to 3.6) 0.12 0%
eGFR ≥60 mL/min
per 1.73 m2
9 678 27.3 (15.7) 0.3 (1.7 to 1.2) 0.34  0.2 (1.4 to 0.9) 0.72  25%
eGFR 45 to
59 mL/min
per 1.73 m2
6 64 28.3 (16.7) 5.4 (11.7 to 0.9) 0.09 0.36 11.7 (12.2 to 11.3) <0.001 <0.001 86%
eGFR 30 to
44 mL/min
per 1.73 m2
2 17 29.7 (18.2) 0.8 (8.8 to 7.2) 0.85 0.43 0.8 (8.8 to 7.2) 0.85 0.88 0%
eGFR 15 to
29 mL/min
per 1.73 m2
0         
eGFR <15 mL/min
per 1.73 m2*
2 51 22.9 (12.8) 6.6 (2.1–11.2) 0.005 0.40 6.6 (2.1–11.2) 0.005 0.005 0%
Total cholesterol
≥4.60 mmol/L
9 434 27.8 (15.6) 0.5 (2.7 to 1.7) 0.66 0.95 0.0 (1.4 to 1.5) 1.00 0.61 39%
Total cholesterol
<4.60 mmol/L
9 298 26.4 (16.2) 0.4 (2.5 to 1.7) 0.73 0.6 (2.4 to 1.2) 0.52 20%
25(OH)D indicates 25-hydroxyvitamin D; ACEi, angiotensin-converting enzyme inhibitor; Aix, augmentation index; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval;
DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IPD, individual participant data; PTH, parathyroid hormone; SBP, systolic blood pressure.
*Or on dialysis.
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this systematic review suggested a large improvement in FMD
in participants with nondialyzed CKD,50 and it therefore
remains possible that individuals with nondialyzed CKD,
particularly with baseline low 25(OH)D levels, might benefit,
although results from trials enrolling nondialyzed CKD partic-
ipants that we included in this review showed improvement in
FMD in only 1 of 3 trials.11,31,34 Similarly, a recently published
substudy using monthly high-dose vitamin D3 showed an
improvement in aortic BP and arterial stiffness measures in
those with baseline 25(OH)D levels <50 nmol/L; effect sizes
were consistent with our IPD analysis findings for this
subgroup. No significant improvements were observed in
the overall trial group, however.51
Pooled observational data show that a loge difference in
PWV (2.7 m/s) corresponds to a 35% to 45% increase in the
risk of a cardiovascular event. A 0.3-m/s improvement in PWV
is therefore unlikely to be associated with a clinically
important reduction in cardiovascular events.52 Furthermore,
it is still possible that agents such as paricalcitol might
provide a greater magnitude of benefit to selected markers
such as FMD. Paricalcitol is an active analogue of vitamin D
(ie, it does not require further hydroxylation before binding to
and activating the vitamin D receptor), and it is possible that
this pharmacological difference from vitamin D2 or D3 might
account for the observed result. It is, however, more likely
that this result is attributed to the play of chance given the
large number of comparisons contained in our analysis.
A modest improvement in microvascular function with
vitamin D was noted in the trial-level analysis, although this
was of smaller magnitude in the IPD analyses and did not
reach significance. The clinical significance of such an
improvement in microvascular function is less clear than for
changes in macrovascular markers, given that there are few
long-term prognostic studies evaluating microvascular
Table 10. IPD Subgroup Analyses for RHI
Subgroup
No. of
Studies n
Mean Baseline
Value (Units)
(SD)
Random Effects Fixed Effects
I2
Treatment Effect
(Units) (95% CI) P Value
P for
Interaction
Treatment Effect
(Units) (95% CI) P Value
P for
Interaction
SBP >140 mm Hg 3 73 1.71 (0.94) 0.21 (0.52 to 0.10) 0.18 0.21 0.14 (0.33 to 0.05) 0.16 0.20 49%
SBP ≤140 mm Hg 3 147 1.62 (0.74) 0.01 (0.11–0.14) 0.85 0.01 (0.11–0.14) 0.85 0%
Baseline 25(OH)D
<25 nmol/L
1 21 1.82 (0.68) 0.23 (0.10 to 0.56) 0.18  0.23 (0.10 to 0.56) 0.18  
Baseline 25(OH)D
25 to 50 nmol/L
3 153 1.71 (0.83) 0.02 (0.19 to 0.16) 0.86 0.19 0.02 (0.09 to 0.14) 0.67 0.24 46%
Baseline 25(OH)D
>50 nmol/L
2 40 1.33 (0.76) 0.21 (0.42 to 0.00) 0.05 0.03 0.21 (0.42 to 0.00) 0.05 0.03 0%
DM 3 110 1.23 (0.74) 0.01 (0.10 to 0.11) 0.91 0.17 0.01 (0.10 to 0.11) 0.91 0.17 0%
No DM 2 101 2.07 (0.63) 0.15 (0.35 to 0.06) 0.16 0.15 (0.35 to 0.06) 0.16 0%
No ACEi or ARB 3 49 1.57 (0.79) 0.42 (0.72 to 1.57) 0.47  0.47 (0.29 to 0.66) <0.001  97%
ACEi, no ARB 3 128 1.75 (0.82) 0.00 (0.16 to 0.15) 0.96 0.48 0.00 (0.14 to 0.13) 0.96 <0.001 27%
ACEi or ARB 3 171 1.67 (0.81) 0.05 (0.21 to 0.11) 0.54 0.43 0.04 (0.15 to 0.07) 0.50 <0.001 46%
PTH >5.0 pmol/L 3 117 1.77 (0.77) 0.02 (0.17 to 0.13) 0.80 0.85 0.02 (0.17 to 0.13) 0.80 0.85 0%
PTH ≤5.0 pmol/L 3 102 1.52 (0.84) 0.00 (0.14 to 0.14) 1.00 0.00 (0.14 to 0.14) 1.00 0%
Ca >2.30 mmol/L 3 127 1.50 (0.81) 0.08 (0.21 to 0.05) 0.21 0.22 0.08 (0.21 to 0.05) 0.21 0.22 0%
Ca ≤2.30 mmol/L 3 93 1.86 (0.76) 0.05 (0.11 to 0.21) 0.55 0.05 (0.11 to 0.21) 0.55 0%
eGFR ≥60 mL/min
per 1.73 m2
3 192 1.69 (0.80) 0.04 (0.14 to 0.07) 0.48 0.81 0.04 (0.14 to 0.07) 0.48 0.77 0%
eGFR <60 mL/min
per 1.73 m2
2 27 1.41 (0.84) 0.10 (0.58 to 0.39) 0.69 0.00 (0.25 to 0.25) 1.00 54%
Total cholesterol
≥4.60 mmol/L
3 60 1.44 (0.85) 0.04 (0.38 to 0.30) 0.81 1.00 0.00 (0.19 to 0.18) 0.98 0.73 43%
Total cholesterol
<4.60 mmol/L
3 141 1.72 (0.81) 0.04 (0.16 to 0.09) 0.57 0.04 (0.16 to 0.09) 0.57 0%
25(OH)D indicates 25-hydroxyvitamin D; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval; DM, diabetes mellitus;
eGFR, estimated glomerular filtration rate; IPD, individual participant data; PTH, parathyroid hormone; RHI, reactive hyperemia index; SBP, systolic blood pressure.
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markers. Differences in the physiological control of small and
large blood vessels, particularly the role of local metabolic
factors in determining microvascular tone, may underpin the
difference in response to vitamin D observed here.
A number of limitations of our analysis require discussion.
Despite the large number of participants, power for subgroup
analyses was limited by the available data; most trials
measured only 1 or 2 vascular outcomes, and some baseline
variables were not collected in all trials. Caution is warranted
in overinterpreting the results of positive associations in the
IPD subgroup analyses; the large number of comparisons
poses a risk of type I statistical error. Conversely, our decision
to combine results from active treatment arms in trials with
more than 1 active treatment arm risks diluting the apparent
size of any treatment effect, although the impact of this is
likely to be minimal given the small number of trials with more
than 1 active treatment arm. For some outcomes,
heterogeneity of measurement techniques required use of
SMDs. Use of SMD limits the clinical utility of the results, and
the heterogeneity of measurements means that translating
SMD results to clinically meaningful values is challenging.
However, use of SMD does at least allow some inferences
about possible effect direction and magnitude to be obtained.
Despite an extensive series of hypothesis-driven subgroup
analyses and metaregressions to examine potential causes for
heterogeneity, we were unable to identify subgroups of
patients more likely to benefit from intervention, and hetero-
geneity in our IPD subgroup analyses remained high. Some of
this heterogeneity may be attributable to the small number of
trials in each analysis, but other, unmeasured sources of real
difference between trials may still exist.
Although the risk of bias in most trials was low, only half of
the included trials analyzed data by intention to treat, and the
inclusion of trials with non-intention-to-treat analyses will tend
Table 11. IPD Subgroup Analyses for Microvascular Function
Subgroup
No. of
Studies n
Random Effects Fixed Effects
I2
Treatment Effect
(SMD) (95% CI) P Value
P for
Interaction
Treatment Effect
(SMD) (95% CI) P Value
P for
Interaction
SBP >140 mm Hg 1 21 0.08 (0.80 to 0.96) 0.86 0.47 0.08 (0.80 to 0.96) 0.86 0.47 
SBP ≤140 mm Hg 3 106 0.44 (0.05–0.82) 0.03 0.44 (0.05–0.82) 0.03 0%
Baseline 25(OH)D
<25 nmol/L
3 46 0.05 (0.54 to 0.64) 0.86  0.05 (0.54 to 0.64) 0.86  0%
Baseline 25(OH)D
25 to 50 nmol/L
3 56 0.20 (0.39 to 0.79) 0.51 0.72 0.20 (0.34 to 0.74) 0.47 0.71 11%
Baseline 25(OH)D
>50 nmol/L
2 26 1.04 (0.14–1.93) 0.02 0.04 1.04 (0.14–1.93) 0.02 0.04 0%
DM 1 18 0.41 (0.54 to 1.35) 0.40 0.91 0.41 (0.54 to 1.35) 0.40 0.91 
No DM 3 111 0.35 (0.03 to 0.73) 0.07 0.35 (0.03 to 0.73) 0.07 0%
No ACEi or ARB 2 70 0.19 (0.28 to 0.66) 0.44  0.19 (0.28 to 0.66) 0.44  0%
ACEi, no ARB 2 29 0.37 (0.38 to 1.13) 0.33 0.69 0.37 (0.38 to 1.13) 0.33 0.69 0%
ACEi or ARB 2 57 0.65 (0.11–1.18) 0.02 0.21 0.65 (0.11–1.18) 0.02 0.21 0%
PTH >5.0 pmol/L 3 70 0.24 (0.24 to 0.72) 0.33 0.54 0.24 (0.24 to 0.72) 0.33 0.54 0%
PTH ≤5.0 pmol/L 2 54 0.47 (0.08 to 1.02) 0.09 0.47 (0.08 to 1.02) 0.09 0%
Ca >2.30 mmol/L 2 25 0.45 (1.25 to 0.35) 0.27 0.10 0.45 (1.25 to 0.35) 0.27 0.10 0%
Ca ≤2.30 mmol/L 2 37 0.43 (0.23 to 1.09) 0.20 0.43 (0.23 to 1.09) 0.20 0%
eGFR ≥60 mL/min
per 1.73 m2
2 86 0.22 (0.21 to 0.64) 0.32 0.46 0.22 (0.21 to 0.64) 0.32 0.46 0%
eGFR <60 mL/min
per 1.73 m2
2 43 0.50 (0.11 to 1.11) 0.11 0.50 (0.11 to 1.11) 0.11 0%
Total cholesterol
≥4.60 mmol/L
3 66 0.05 (0.47 to 0.57) 0.85 0.32 0.05 (0.45 to 0.54) 0.85 0.31 7%
Total cholesterol
<4.60 mmol/L
3 61 0.42 (0.10 to 0.94) 0.11 0.42 (0.10 to 0.94) 0.11 0%
25(OH)D indicates 25-hydroxyvitamin D; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval; DM, diabetes mellitus;
eGFR, estimated glomerular filtration rate; IPD, individual participant data; PTH, parathyroid hormone; SBP, systolic blood pressure; SMD, standardized mean difference.
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to inflate observed effect sizes. It is also possible that not all
eligible trials were found or included; for some trials,
published trial reports had not been produced or could not
be obtained from the authors. New trials continue to be
published in this area, but most continue to use small
numbers of participants and are likely to have limited impact
on our conclusions. Not all authors were willing to share their
IPD, and not all trial reports contained sufficient information
to allow data to be extracted for meta-analysis. A further
limitation is inherent in the populations studied; most
populations contained only a minority of participants with
25(OH)D levels below 25 nmol/L, a group that would be
thought to be most likely to benefit. Similarly, some trials
were conducted in groups without overt vascular disease,
where again the possibilities for improving vascular function
might have been limited. Most trials were conducted in white
populations, which potentially limits the generalizability of the
findings. In particular, few blacks were enrolled in the included
studies; this group have particularly low 25(OH)D levels when
living at high latitudes and may be more likely to show a
reduction in BP with vitamin D supplementation.53
A range of vitamin D doses were used in the included trials;
debate continues as to what dose of vitamin D is optimum or
indeed what the target level of 25(OH)D should be. If a level of
75 nmol/L is regarded as optimum as has been suggested
from observational studies,54 doses at the upper end of the
range included in this analysis are required to reach this
level.40,55,56 Metaregression of vitamin D dose versus treat-
ment effect suggested that higher doses of vitamin D were
associated with a slightly greater treatment effect for FMD,
but not for PWV or AIx. We found no evidence that daily
dosing was more efficacious than intermittent dosing, despite
previous work that has suggested that daily dosing provides
more-consistent tissue exposure to the parent compound,
Table 12. IPD Subgroup Analyses for Aortic SBP
Subgroup
No. of
Studies n
Mean Baseline
Value (mm Hg)
(SD)
Random Effects Fixed Effects
I2
Treatment Effect
(95% CI) (mm Hg)
P
Value
P for
Interaction
Treatment Effect
(95% CI) (mm Hg) P Value
P for
Interaction
SBP >140 mm Hg 5 79 141.4 (26.3) 0.4 (8.8 to 9.6) 0.93 0.95 0.4 (5.5 to 6.3) 0.90 0.82 57%
SBP ≤140 mm Hg 7 319 115.8 (19.1) 0.1 (3.3 to 3.5) 0.96 0.3 (2.4 to 1.9) 0.82 51%
Baseline 25(OH)D
<25 nmol/L
6 77 114.2 (28.7) 2.7 (9.8 to 4.4) 0.46  1.7 (5.9 to 2.5) 0.42  50%
Baseline 25(OH)D
25 to 50 nmol/L
7 148 121.9 (24.7) 2.9 (6.0 to 0.3) 0.08 0.96 2.9 (6.0 to 0.3) 0.08 0.65 0%
Baseline 25(OH)D
>50 nmol/L
6 171 123.0 (20.1) 0.7 (3.8 to 5.1) 0.76 0.43 1.2 (1.9 to 4.2) 0.45 0.27 24%
DM 4 45 119.3 (35.3) 9.4 (0.2 to 19.1) 0.06 0.17 7.9 (0.3 to 15.4) 0.04 0.006 26%
No DM 7 355 120.9 (22.0) 1.6 (13.8 to 10.6) 0.80 3.0 (5.1 to 1.0) 0.004 97%
No ACEi or ARB 5 138 111.8 (24.1) 6.1 (11.8 to 0.4) 0.04  5.8 (9.1 to 2.1) <0.001  51%
ACEi, no ARB 3 78 130.4 (22.1) 5.4 (10.8 to 0.1) 0.05 0.87 5.4 (10.8 to 0.1) 0.05 0.9 0%
ACEi or ARB 4 173 132.6 (23.7) 3.1 (7.1 to 0.8) 0.12 0.40 3.1 (7.1 to 0.8) 0.12 0.32 0%
PTH >5.0 pmol/L 6 168 121.0 (27.5) 1.0 (4.3 to 2.3) 0.55 0.52 1.0 (4.3 to 2.3) 0.55 0.67 0%
PTH ≤5.0 pmol/L 6 154 123.1 (24.0) 2.8 (8.2 to 13.8) 0.62 1.9 (5.6 to 1.8) 0.31 85%
Ca >2.30 mmol/L 2 30 118.4 (20.0) 0.3 (5.5 to 6.0) 0.93 0.61 0.3 (5.5 to 6.0) 0.93 0.61 0%
Ca ≤2.30 mmol/L 3 120 121.9 (25.9) 2.0 (0.9 to 5.0) 0.18 2.0 (0.9 to 5.0) 0.18 0%
eGFR ≥60 mL/min
per 1.73 m2
5 300 120.0 (17.7) 1.3 (4.8 to 2.2) 0.47 0.70 0.6 (2.8 to 1.5) 0.56 0.92 59%
eGFR <60 mL/min
per 1.73 m2
4 44 130.9 (20.2) 0.8 (9.2 to 10.9) 0.87 0.9 (6.3 to 4.6) 0.76 69%
Total cholesterol
≥4.60 mmol/L
5 158 122.2 (21.6) 2.3 (5.8 to 1.2) 0.20 0.68 2.3 (5.8 to 1.2) 0.20 0.76 0%
Total cholesterol
<4.60 mmol/L
5 138 122.5 (27.5) 0.7 (7.5 to 6.1) 0.83 1.5 (5.3 to 2.4) 0.45 66%
25(OH)D indicates 25-hydroxyvitamin D; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval; DM, diabetes mellitus;
eGFR, estimated glomerular filtration rate; IPD, individual participant data; PTH, parathyroid hormone; SBP, systolic blood pressure.
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facilitating uptake and autocrine activation,57 and evidence
that daily dosing may be more efficacious in some conditions
(eg, respiratory disease).58 Our results are consistent with our
previous analysis that did not find a difference between daily
and intermittent dosing on BP.5 A final explanation that
requires consideration is that the duration of therapy in most
trials may simply have been too short to produce biological
effects—particularly those trials intervening for only a few
weeks. This explanation is plausible for outcomes such as
arterial stiffness if biological effects are mediated by changes
in vascular calcification, but seems less so for outcomes such
as FMD and reactive hyperemia index, where other interven-
tions are known to alter these parameters within days or
weeks. Further evidence against this hypothesis is provided
by the metaregression results, which suggest that longer trial
duration was associated with a smaller treatment effect for
FMD.
The results of these analyses add to the growing body of
evidence suggesting that vitamin D supplementation may not
have any beneficial effects on cardiovascular health. The lack
of effect on vitamin D supplementation on BP in most studies
to date5,53 and the lack of effect on vascular markers
observed in the current analysis suggests that associations
between 25(OH)D levels and cardiovascular events observed
in observational studies may not be causal. Not all observa-
tional studies have been prospective in nature, and the degree
of adjustment for confounders has been variable. There are
several reasons why assumptions about causality may be
incorrect, including reverse causality (where overt or preclin-
ical illness leads to lower 25(OH)D levels through mechanisms
such as immobility, obesity, or inflammation59,60), and
confounding by shared risk factors for both cardiovascular
disease and low 25(OH)D levels; obesity, inactivity, smoking,
and advanced age are all known to be associated with lower
Table 13. IPD Subgroup Analyses for Aortic DBP
Subgroup
No. of
Studies n
Mean Baseline
Value (mm Hg)
(SD)
Random Effects Fixed Effects
I2
Treatment Effect
(95% CI) P Value
P for
Interaction Treatment Effect (95% CI) P Value
P for
Interaction
SBP >140 mm Hg 5 79 79.8 (11.1) 0.7 (3.3 to 2.0) 0.62 0.95 0.7 (3.3 to 2.0) 0.62 0.95 0%
SBP ≤140 mm Hg 7 320 75.7 (9.3) 0.6 (1.9 to 0.6) 0.33 0.6 (1.9 to 0.6) 0.33 0%
Baseline 25(OH)D
<25 nmol/L
6 77 75.8 (9.5) 1.0 (2.4 to 4.5) 0.56  1.0 (2.4 to 4.5) 0.56  0%
Baseline 25(OH)D
25 to 50 nmol/L
7 151 77.2 (10.0) 0.7 (2.8 to 1.3) 0.48 0.41 0.7 (2.8 to 1.3) 0.48 0.41 0%
Baseline 25(OH)D
>50 nmol/L
6 171 76.3 (10.0) 0.5 (2.0 to 1.0) 0.52 0.43 0.5 (2.0 to 1.0) 0.52 0.43 0%
DM 4 45 74.0 (11.5) 3.8 (1.6 to 9.1) 0.17 0.12 2.8 (0.1 to 5.4) 0.04 0.02 68%
No DM 7 355 76.9 (9.6) 0.6 (1.9 to 0.6) 0.29 0.6 (1.9 to 0.6) 0.29 0%
No ACEi or ARB 6 152 75.4 (9.8) 0.5 (2.6 to 1.5) 0.61  0.5 (2.6 to 1.5) 0.61  0%
ACEi, no ARB 4 92 79.3 (11.4) 0.6 (1.9 to 3.1) 0.62 0.50 0.6 (1.9 to 3.1) 0.62 0.50 0%
ACEi or ARB 4 173 78.4 (10.5) 0.4 (2.2 to 1.4) 0.69 0.94 0.4 (2.2 to 1.4) 0.69 0.94 0%
PTH >5.0 pmol/L 6 169 77.3 (10.2) 0.1 (2.3 to 2.5) 0.93 0.62 0.1 (2.3 to 2.5) 0.93 0.59 0%
PTH ≤5.0 pmol/L 6 154 77.2 (10.4) 0.7 (2.7 to 1.3) 0.52 0.7 (2.4 to 1.0) 0.39 17%
Ca >2.30 mmol/L 2 31 79.3 (9.8) 0.4 (4.7 to 5.5) 0.88 0.94 0.4 (4.7 to 5.5) 0.88 0.94 0%
Ca ≤2.30 mmol/L 3 120 77.0 (10.2) 0.2 (1.6 to 1.9) 0.86 0.2 (1.6 to 1.9) 0.86 0%
eGFR ≥60 mL/min
per 1.73 m2
5 300 77.3 (9.2) 0.6 (1.8 to 0.7) 0.35 0.07 0.6 (1.8 to 0.7) 0.35 0.03 0%
eGFR <60 mL/min
per 1.73 m2
4 45 75.5 (9.2) 4.6 (0.9 to 10.1) 0.10 2.9 (0.1 to 5.9) 0.06 46%
Total cholesterol
≥4.60 mmol/L
5 158 77.3 (9.5) 0.6 (2.6 to 1.3) 0.52 0.76 0.6 (2.6 to 1.3) 0.52 0.89 0%
Total cholesterol
<4.60 mmol/L
5 138 74.5 (9.8) 0.0 (3.3 to 3.4) 0.98 0.8 (3.0 to 1.3) 0.45 49%
25(OH)D indicates 25-hydroxyvitamin D; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; Ca, calcium; CI, confidence interval; DBP, diastolic blood
pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IPD, individual participant data; PTH, parathyroid hormone; SBP, systolic blood pressure.
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25(OH)D levels, and such confounding is notoriously difficult
to fully adjust for. Existing evidence from meta-analyses of
vascular events in osteoporosis trials using vitamin D does
not support an effect of vitamin D in lowering cardiovascular
event rates,1,7 with the possible exception of heart failure, and
the first of a new wave of large, population-based vitamin D
trials has recently reported, again showing no effect of vitamin
D supplementation on cardiovascular event rates.8 Random-
ized trials of relatively short duration cannot exclude a benefit
of vitamin D supplementation over the span of a lifetime;
observational designs including Mendelian randomization
studies61 may still be the only way to shed light on very
long exposures to vitamin D, although even these designs are
subject to bias and confounding.
A number of other large vitamin D trials are due to report
over the next 3 to 4 years,62 and most of these include
cardiovascular events as key outcomes—outcomes which our
analysis did not focus on. Existing evidence does not support
the use of vitamin D to reduce cardiovascular risk, and the
results of our analysis do not suggest a specific target group
that is particularly likely to benefit from vitamin D supple-
mentation, although we found no evidence of a deleterious
effect on cardiovascular function. The relative lack of
representation of some groups, particularly nonwhite groups,
tempers the generalizability of this conclusion. In the absence
of a subgroup with clear benefit, and with large trial reports
expected soon, further small-scale trials examining surrogate
vascular end points are unlikely to advance this field of
research significantly.
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